• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The invention relates to medicine, specifically to the medical industry, and concerns a method for obtaining a granulate from aqueous solutions of extractives from protein-free calf blood. The aim of the invention is to increase the stability of the target product. The method is carried out by drying and granulating simultaneously with microcrystalline cellulose and cross-linked polyvinylpyrrolidone in the ratio 1: 1 or a mixture of microcrystalline cellulose and cross-linked sodium carboxymethylcellulose in the ratio 1.5: 1 in the amount of 38-40, 8% relative to the dry mass of the granulate, feeding them into a fluidized bed granulator, applying dry air at 80 ° C and a flow rate of 500-800 m3 / h, while spraying onto carriers at a speed of 70-600 g / min 20% water A solution of extractives from protein-free calf blood containing 1-vinyl-2-pyrrolidone as a binder, in a fluid-bed granulator, maintains a temperature of 28-32 ° C and a humidity of 15-20%, after injection 75- 76.4% of the total amount of the solution is reduced to 30 ° C and the rest of the solution is injected at the same rate with a moisture content of 35-45% by weight and 49.1% of the solution is injected, the spray rate is increased to 900 g / min the dry granulate formed with a particle size of 0.06-0.8 mm is dried by raising the temperature to 60-80 ° C, residual moisture is removed by raising the temperature of the granulate to 43 ° C. 6 tab. sl S -h 4 CJ SB SB Sl)
    公开号:SU1743334A3
    申请号:SU864028373
    申请日:1986-10-03
    公开日:1992-06-23
    发明作者:Клюг Отто；Шлюнкен Хайнрих；Зигель Дитмар
    申请人:Хормон-Хеми Мюнхен Гмбх (Фирма)；
    IPC主号:
    专利说明:

    The invention relates to medicine, in particular to the medical industry, and concerns a method for producing a granulate from aqueous solutions of extractives from protein-free body blood.
    The nitrogen-free extractives from deproteinized blood of the body contain low molecular weight components of this blood, which have a beneficial effect on the blood flow in the tissue and thereby accelerate wound healing. In addition, these nitrogen-free extractives are used in the treatment of circulatory disorders and metabolism in the brain.
    The aim of the invention is to increase the stability of the target product.
    PRI me R 1. Load a capacity of 3000 g of a mixture of equal weight parts of the Avtsel PH-101 (microcrystalline cellulose) and polyplasd (cross-linked polyvinylpyrrolidone) 40.8% relative to the content of extractive substances to the finished product and create in it a fluidized layer by blowing in dry air with a bulk velocity of 500 m3 / h at 80 ° C.
    20 liters of a 20% aqueous solution of nitrogen-free extractive substances are mixed with 1 liter of a 20% aqueous solution of colidone K 25 (polymer 1-vinyl-2-pyrrolidone), at 10 wt.h. extractives account for 0.5 wt. Vinyl-2-pyrrolidone is fed to a double nozzle using a screw pump and injected into a fluidized bed. The injection rate is chosen in such a way that the temperature of the fluidized bed in the granulator is 28–30 ° C, and the stationary humidity of the material in the fluidized bed is 15 wt.% So that the amount of water entering the granulator and the water evaporating from it is equal. there was no agglomeration.
    To realize these conditions, the average spray rate is 70 g of solution per minute. After injection of 3/4 of the total amount of the solution (75%), the temperature of the supplied air is reduced to 30 ° C and the rest of the solution is injected at the same rate. The constant moisture content in the fluidized bed increases and at 35-45 wt.%, Preferably 38-40 wt.%, The powder agglomerates. In this case, the moisture content of the granulation is continued until a granulate with a particle diameter of 0.06-0.8 mm is formed from the total amount of powder. After the injection is finished, the solution injection temperature is increased to 60-80 ° C, as a result of which the drying process begins. The temperature of the granulate during drying is 30-32 ° C. Drying ends when the temperature of the granulate begins to increase. To remove residual moisture, the granulation is kept for 15 minutes at 43 ° C. As a result, after approximately 6 hours, 7,350 g of granulate having the characteristics shown in Table 1 are obtained.
    PRI mme R 2. The process is carried out in the same manner as in the case of Example 1, but 3000 g of microcrystalline cellulose (Avg. WP 101) is used as a filler and carrier, and as a binder, add to the solution of nitrogen-free extractives 1 l of a 20% aqueous solution of 1-vinyl-pyrrolidone polymer - kollidon 90. The process takes about 6 hours.
    The result is a granulate.
    Characteristics of the granulate are given in table. 2
    Example 3. A container for a 60-liter fluidized-bed material with a volume of 60 liters was loaded with 15,000 g of Avicel WP 101 (microcrystalline cellulose) and 10,000 g of AC-DI-Sol (crosslinked sodium carboxymethylcellulose) 1.5: 1. By supplying an air granulator with a bulk velocity of 800 m / h and a temperature of 80 ° C, a fluidized bed is created. 166.6 l of a 20% aqueous solution of nitrogen-free extractive substances are mixed with a solution of 1660 g of collidone K 25, 40 wt.% Of the total dry weight of extractive substances, in 16.6 l of water using a worm pump through three nozzles with nozzles 1.2 mm in diameter, it is injected into the fluidized bed. With a spraying rate of about 600 g of aktovegin and kollidon solution in 1 minute, a stationary temperature of 30-32 ° C and a steady-state humidity of about 15% are established in the fluidized bed.
    After the injection of 140 l (76.4%) of the solution under these conditions, the temperature of the supplied air is lowered to room temperature, the humidity is increased, and the conditions for the start of agglomeration are created. After the solution has been injected, the resulting granulate is dried in a fluidized bed at an inlet air temperature of 80 ° C. The process takes about 6 hours.
    The resulting dry granulate has the characteristics given in table. 3
    Example 4. In a container for a material of a granulator with a fluidized bed of 60 liters, 22000 g of microcrystalline cellulose (Avtseltl PH 101) is loaded. By feeding air into the granulator with a bulk velocity of 800 m3 / h and a temperature of 70 ° C, a stable fluidized bed is created. 166.6 l of aktovegin's 20% aqueous solution (nitrogen-free extractives from calf blood) is mixed with a solution of 1660 g of kollidon 90 (polymer 1-vinyl-2-pyrrolidone), 38% by weight of the content of extractive substances in 16.6 liter of water and using a screw pump inject through three nozzles with a nozzle diameter of 1.2 mm into the fluidized bed. With an initial spray rate of about 600 grams of Actovegin and Kollidon 90 grams in 1 minute, a steady-state temperature of 32-32 ° C and a steady-state humidity of about 15% are set in the fluidized bed.
    After 2.5 hours at the same supply air temperature, the rate after injection of 49.1% of the total amount of the spray solution is increased to 900 g of solution per minute. This begins agglomeration. After the injection of the solution is completed, the resulting granulate is dried in a fluidized bed at an inlet air temperature of 70 ° C, humidity 38-40%. The process takes about 5 hours.
    The resulting dry granulate has the characteristics given in table. four.
    PRI me R 5. Core dragee.
    7200 g of the granulate obtained by the method in accordance with Example 1 is mixed with 60 g of magnesium stearate and 40 g of talc and compressed in a circulating device in drag weighing 365 mg at a pressure of 78.5-150 N / mm. The dragées obtained in this way have the following characteristics.
    Derder characteristics: diameter 10.0 mm, thickness 5.5 mm, fracture resistance 115 N, abrasion (4 min) 20.1%, destruction 8-10 min.
    Composition, mg (%): extractives 200 (53.3); polyplasdone 75 (20,0); aviation objective PN 101 75 (20.0); Kollidon K 25 10 (2.7); talc 2 (0.5); magnesium stearate 3 (0.8); water content is 9.7 (2.6). Dragas prepared in this way have the same content of nitrogen-free extractives, and a constant water content. When stored for 24 months at room temperature, their quality does not deteriorate and does not show signs of staining.
    PRI me R 6. Tablets.
    7200 g of the granulate obtained by the method in accordance with Example 1 is mixed with 60 g of magnesium stearate and pressed into a circulation device into tablets weighing 730 mg at a pressure of 98.1-196.2 N / mm2. Thus obtained tablets have the following characteristics:
    Characteristics of the tablets: length 18 mm, width 7 mm, thickness 6.7 mm, fracture resistance 180 N, abrasion (4 min) 0.1%, destruction 10 min.
    Composition, mg (%): nitrogen-free extractives 400 (53.4); polyplasd 150 (20,0); Avicarge PH 101 150 (20.0), Kollidon K 25 20 (2.7); talc 4 (0.5); magnetic stearate 6 (0.8); water content is 19 (2.5).
    Example. Kernel jelly beans.
    7200 g of the granulate obtained according to Example 3, however, AC-DI-Sol and the Avtsel PH 101 in a 1: 1 ratio are introduced, mixed with 72 g of talc and 108 g of magnesium stearate and pressed at a pressure of 78.5-150 N / mm in the pills weighing about 367 mg.
    Der properties: diameter 10 mm, thickness 5.5 mm, strength 62 N, abrasion (4 min) 0.1%, destruction 6.5 - 7 min.
    Composition, mg%: extractives 200 (53.5); Avictsel PH 101 75 (20.1); AC-DI-Sol 75 (20.1); Kollidon K25 10 (2.7); talc 2 (0.6); stearate M 3 (0.8); water content is 8.6 (2.3).
    The stability of the target product is determined by its moisture content (Tables 5 and 6), as well as by comparing the color of the preparations, the dosage forms, the manufacture according to the prototype, in a certain period decomposed and changed their color to brown, while the dosage forms made according to the proposed way, remained white.
    The duration of the process is significantly reduced, in the proposed method it is 5-6 hours, according to the prototype it is several days.
    The preparation of Actovegin forte dragees from the lyophilisate of the active substance in the ordinary granulation process is shown in Table five.
    The preparation of Actovegin forte dragee from an aqueous extract of the active substance by granulation in the fluidized bed is shown in Table. 6
    Fo rumula and z obre n i A method of obtaining a granulate from aqueous solutions of extractive substances, protein-free calf blood, suitable for pressing into a solid dosage form, by mixing it with a vehicle, carrier and binder , drying and granulating, characterized in that, in order to improve the quality of the target product by increasing the stability in the manufacture of the dosage form and reducing the process time, drying and granulating are carried out simultaneously with the use as a filler and microcrystalline cellulose carrier or a mixture of microcrystalline cellulose and cross-linked polyvinylpyrrolidone in a ratio of 1: 1, or a mixture of microcrystalline cellulose and cross-linked sodium carboxymethylcellulose in a ratio of 1.5: 1 in the amount of 38-40.8% relative to the dry matter of the granulate, feed them into a fluidized bed granulator with a dry air supply at 80 ° C; flow rates of 500-800 m3 / h; a carrier is sprayed at a speed of 70-600 g / min to a carrier-free 20% aqueous solution of protein-free bovine blood, containing on 10 ma.ch. extractives 0.5 wt.h. 1-vinyl-2-pyrrolidone as a binder in a dissolved state,
    moreover, the fluid bed granulator maintains a temperature of 28-32 ° C and a humidity of 15-20%, after injection of 75-76.4% of the total amount of the solution, the temperature of the supplied air is reduced to -30 ° C and the rest of the solution is injected with that the same speed with a moisture content of 35-45 wt.%, or after the injection of 49.1% of the total amount of the solution at the same supply air temperature, the spray rate is increased to 900 g / min and the remaining solution
    0
    Injecting 35–45% by weight to the moisture content of the layer in the pre-liquefying layer, the dry granulate formed with the particle size of 0.06–0.8 mm is dried by increasing the temperature of the injected liquid gas to 60–80 ° C. The residual moisture is removed by increasing the temperature of the granulate to 43 ° C for 15 minutes and granules are obtained containing 54-57% of extractive substances based on the total mass of the granulate in a dry state with a particle diameter of 0.06-0.8 mm .
    Components
    Content of extractive
    substances
    Kollidon 90
    Avitsel PH 101
    The remaining moisture content
    The diameter of the granules
    Method parameters
    Content of extractive substances Avitsel PH 101 AC-DI-Sol Kollidon 90 Residual moisture Loose weight, g / cm Loose weight after compaction, g / cm
    Fluidity, g / cm2 with granule size, microns
    Table 1
    table 2
    Hitch, g
    Analytically determined mg / r granulate (%)

    544.2 (54.4) 27.3 (2.7)
    408.0 (40.8) 20.0 (3.0)
    0.08-0.8 mm
    Table 3
    Hitch, g
    Analytically determined mg / r granulate (%)
    547.1 (54.7)
    246.0 (24.6)
    164.1 (16.4) 27.3 (2.7) 16.0 (1.6)
    0.53
    0.63
    12.3
    60-500
    Method parameters
    Content of extractive substances Avitsel PH 101 Kollidon 90 Residual moisture Bulk weight, g / cm3 Bulk weight after compaction, g / cm
    Fluidity, g / cm3 С Size of granules, micron
    The moisture content is determined by the Karl-Fisher method.
    Table 4
    Hitch, g
    Analytically determined mg / g granulate (%)
    575.2 (57.5)
    379.7 (38.0)
    28.9 (2.9)
    16.0 (1.6)
    0.53
    0.63
    12.30
    60-500
    Table 5
    Table 6
    The moisture content is determined by the Karl-Fisher method.
    Continuation of table 6
    权利要求:
    Claims (1)
    [1]
    Claim
    A method of producing granulate from aqueous solutions of protein-free calf blood extractives suitable for compression into a solid dosage form by mixing it with a filler, a carrier and a binder, drying and granulating, characterized in that, in order to improve the quality of the target product by increasing stability in the manufacture of the dosage form and the reduction of the process time, drying and granulation are carried out simultaneously using microcrystalline as a filler and carrier cellulose or a mixture of microcrystalline cellulose and crosslinked polyvinylpyrrolidone in a ratio of 1: 1, or a mixture of microcrystalline cellulose and crosslinked sodium carboxymethyl cellulose in a ratio of 1.5: 1 in an amount of 38-40.8% relative to the dry matter of the granulate, feeding them into a granulator with a fluidized bed, dry air at 80 ° C, flow rates of 500-800 m 3 / h, a 20% aqueous solution of extractives from protein-free calf blood containing 10 wt.% is sprayed onto the carriers at a speed of 70-600 g / min. h extractive substances 0.5 wt.h. Vinyl-2-pyrrolidone as a binder in a dissolved state,
    Ί moreover, in a granulator with a fluidized bed, a temperature of 28-32 ° C and a humidity of 15-20% are maintained, after injection of 75-76.4% of the total amount of the solution, the temperature of the supplied air is reduced to a temperature of -30 ° C and the rest of the solution is injected with the same rate at a moisture content of 35-45 wt.%, or after injection of 49.1% of the total amount of the solution at the same temperature of the supplied air, the spray rate is increased to 900 g / min and the remaining solution is injected while maintaining the moisture content all the time to and the same n of the n layer 35-45 wt.%, s the formed granulate with a particle size of 0.06-0.8 mm is dried by increasing the temperature of the injected liquid gas to 60-80 ° C, residual moisture is removed by raising the temperature of the granulate to 43 ° C for 15 minutes and a granulate containing 54-57 is obtained % of extractive substances from the total mass of the granulate in a dry state with a particle diameter of 0.06-0.8 mm
    Table 1
    Components Hitch, g Analytically determined, mg / g granulate (%) Extractive Content 4000 544.2 (54.4) Kollidon K-25 200 27.3 (2.7) Avicel PH 101 1500 204.0 (20.4) Polyplazdone 1500 204.0 (20.4) The remaining moisture content20.0 (2.0) Pellet diameter0.88-0.8 mm
    table 2
    Components Hitch, g Analytically determined, I mg / granulate (%) Extractive Content 4000 544.2 (54.4) Collidon 90 200 27.3 (2.7) Avicel PH 101 3000 408.0 (40.8) The remaining moisture content20.0 (3.0) Pellet diameter0.08-0.8 mm
    Table 3
    Method Parameters Hitch, g Analytically determined, mg / g granulate (%) Extractive Contentsubstances. 33320 547.1 (54.7) Avicel PH 101 15,000 246.0 (24.6) AC-DI-Sol 10,000 164.1 (16.4) Collidon 90 1660 27.3 (2.7) Residual moisture16.0 (1.6) Bulk weight, g / cm 3 0.53 Bulk weight after compactionNy, g / cm 3 0.63 The fluidity, g / cm 2 · s12.3 The size of the granules, microns60-500
    Table 4
    Method Parameters Hitch, g Analytically determined, mg / granulate (%) Extractive Content 33320 575.2 (57.5) Avicel PH 101 22000 379.7 (38.0) Collidon 90 1600 28.9 (2.9) Residual moisture16.0 (1.6) Bulk weight, g / cm 3 Bulk weight after compaction0.53 Ny, g / cm 3 0.63 Fluidity, g / cm 3 * s12.30 The size of the granules, microns60-500
    Table 5
    Loading Humidity lyophilisate% Humidity dragees,% The increase in moisture lyophilisate, dragees% 27 1621 0.94 3.322,38 27 16 11 0.85 3.302.45 27 12 31 0.85 3.192,34 27 12 21 0.71 3.282,57 27 08 21 0.83 3.082.25 27 08 11 0.43 2.902,4,7 27 04 11 0.82 2.872.05 27 02 31 0.87 2.451,58 26 49 21 0.93 2.481.55 26 49 11 0.79 2.481,67 26 50 31 0.77 2.711.94 26 50 21 0.91 2.761.85 26 45 21 0.72 3.853.13 27 23 11Average 0.87 3.852.48 value 0.81 3.002.19 Standard deviation ± 0.13 ± 0.41± 0.44 number downloads AND 1414
    The moisture content is determined by the Karl-Fischer method.
    Table 6
    Loading The moisture content of the granulate,% Humidity dragees,% The increase in humidity] granulate-dragee,% 1 2 3 4 27 38 21 1.00 2.90 1.90 27 44 21 0.80. 2.70 1.90 27 44 22 0.90 2.20 1.30 27 47 21 1.00 3.13 2.13 27 47 22 1.09 2.94 1.85 27 50 33 0.98 2,35 1.37 27 50 34 0.84 2,32 1.48 27 53 21 0.81 2.10 1.29 27 53 22 0.81 2,50 1,69 28 01 11 0.67 2,50 1.77
    Continuation of Table 6
    1 2 3 4 28 01 12 0.76 2.70 1.94 28 03 31 0.90 2,30 1.40 28 03 32 0.80 2.40 1,60 28 03 33 0.90 2,32 1.33 Mean 0.88 2,53 1,64 Standard deviation ± 0.11 ± 0.30 ± 0.28 Download Count 14 14 14
    The moisture content is determined by the Karl-Fischer method.
    20Compiled by S. Melnikov Editor N. Gunko Tehred M. Morgenthal Corrector N. Revskaya
    Order 2296 Circulation Subscription
    VNIIIPI of the State Committee for Inventions and Discoveries at the State Committee for Science and Technology
    113035, Moscow, Zh-35, Raushskaya nab., 4/5
    Production and Publishing Combine Patent, Uzhgorod, 101 Gagarin St.
    类似技术:
    公开号 | 公开日 | 专利标题
    US4666704A|1987-05-19|Controlled release delivery system for macromolecules
    US4900557A|1990-02-13|Pellet formulation
    US5091185A|1992-02-25|Coated veterinary implants
    US4837031A|1989-06-06|Compositions containing ibuprofen
    US4489026A|1984-12-18|Process for preparing solid unit dosage forms of ultra-low dose drugs
    RU2284183C2|2006-09-27|Composition for animal growth controlling, method for production and uses thereof
    US4710519A|1987-12-01|Process for preparing spray dried acetaminophen powder and the powder prepared thereby
    IL134079A|2004-12-15|Process for the preparation of pellets with a content of up to 90 wt.% of a pharmaceutical active ingredient
    SU1743334A3|1992-06-23|Process for producing granulate from aqueous solutions of extractive substances of protein-free calfъs blood
    US3697640A|1972-10-10|Rumen stable medicament and/or nutrient compositions
    EP1267828B1|2006-08-02|Pharmaceutical preparations containing saccharose fatty acid esters for controlling the release of active ingredients
    US4937083A|1990-06-26|Feed additive for ruminants
    US5531994A|1996-07-02|Feed additive containing zinc bacitracin
    US6077534A|2000-06-20|Production of pharmaceutical formulations for treatment of edema and venous disorders
    US5156851A|1992-10-20|Coated veterinary implants
    US10258573B2|2019-04-16|Micronized insulin and micronized insulin analogues prepared under acidic conditions, and methods of manufacturing the same under acidic conditions
    US5089276A|1992-02-18|Calcium pantothenate composite
    NZ533085A|2005-10-28|Micropherules containing a pleuromutilin derivative
    US5232708A|1993-08-03|Coated veterinary implants
    EP0314421A1|1989-05-03|Somatotropin formulations
    CZ299252B6|2008-05-28|Method of producing encased spherical pellets
    RU2203042C2|2003-04-27|Pharmaceutical composition and method for its preparing
    CN111821266B|2021-09-14|Taurine sustained-release composition and preparation method thereof
    SI8611694A8|1996-08-31|Method for simultaneous extract of dry substance from calf's blood extract acqueous solution devoited of proteins.
    HU191102B|1987-01-28|Process for producing pharmaceutical compositions of regulated dissolution of the active agents containing water-soluble inorganic pharmacons
    同族专利:
    公开号 | 公开日
    EP0223033A3|1988-06-29|
    EP0223033A2|1987-05-27|
    CS261898B2|1989-02-10|
    PL261696A1|1988-01-07|
    HU196712B|1989-01-30|
    JPS6287518A|1987-04-22|
    DK167843B1|1993-12-27|
    CA1268706A|1990-05-08|
    JPH0717512B2|1995-03-01|
    CS708486A2|1988-06-15|
    EP0223033B1|1991-07-10|
    AT65026T|1991-07-15|
    DE3680183D1|1991-08-14|
    BG49498A3|1991-11-15|
    DK472886A|1987-04-05|
    HUT42328A|1987-07-28|
    ES2038587T3|1993-08-01|
    PL148336B1|1989-10-31|
    US4753803A|1988-06-28|
    GR3002290T3|1992-12-30|
    DD258992A1|1988-08-10|
    YU44931B|1991-04-30|
    YU169486A|1987-12-31|
    DE3535536A1|1987-04-09|
    DK472886D0|1986-10-03|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    DE1076888B|1956-12-18|1960-03-03|Karl Heinz Jaeger Dr Med|Process for the production of active substances that promote breathing for therapeutic purposes|
    US3458622A|1967-04-07|1969-07-29|Squibb & Sons Inc|Controlled release tablet|
    DE2143519B2|1971-08-31|1974-05-30|Sandoz Ag, 8500 Nuernberg|Process for fluidized bed granulation of pharmaceutical mixtures in powder form|
    AT330953B|1972-11-16|1976-07-26|Solco Basel Ag|METHOD OF MANUFACTURING A PHARMACEUTICAL PREPARATION FOR IMPROVING CELL RESPIRATION|
    DE3237303A1|1982-10-08|1984-04-12|Glatt GmbH, 7851 Binzen|DEVICE FOR A FLUIDIZED LAYER PROCESS AND A PROCESS THEREFOR|
    EP0106309A3|1982-10-12|1986-12-30|Kailash Kumar Dr. Prof. Gauri|Biologically active extracts, process for their manufacture, medicinal and cosmetical preparations comprising them, and their use as additives in foodstuffs and stimulants|
    US4662880A|1986-03-14|1987-05-05|Alza Corporation|Pseudoephedrine, brompheniramine therapy|US5017383A|1989-08-22|1991-05-21|Taisho Pharmaceutical Co., Ltd.|Method of producing fine coated pharmaceutical preparation|
    DE4441167C1|1994-11-18|1996-03-14|Fraunhofer Ges Forschung|Prodn. of blood plasma as virus free dry granulate|
    US6083532A|1995-03-01|2000-07-04|Duramed Pharmaceuticals, Inc.|Sustained release formulation containing three different types of polymers and tablet formed therefrom|
    ES2183606T5|1998-12-23|2008-05-16|Csl Behring Gmbh|GRANULATE FIBRINE ADHESIVE AND PROCEDURE FOR PREPARATION.|
    TWI252111B|2001-12-14|2006-04-01|Solvay Pharm Gmbh|Matrix film tablet with controlled release of a natural mixture of conjugated estrogens|
    TWI332400B|2001-12-14|2010-11-01|Solvay Pharm Gmbh|Preformulation for the tableting of natural mixtures of conjugated estrogens|
    DE102008014237A1|2008-03-14|2009-09-17|J. Rettenmaier & Söhne Gmbh + Co. Kg|Directly compressible tableting aid|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    DE19853535536|DE3535536A1|1985-10-04|1985-10-04|METHOD FOR SIMULTANEOUS DRYING AND GRANULATING EXTRACT MATERIALS FROM DEFROSTED CALF BLOOD|
    [返回顶部]